ISSN: 1859 - 2872
Determination of plasma MMP-2 and TIMP-2 levels in patients with hypopharyngeal and laryngeal cancer
Main Article Content
Keywords
Abstract
Objective: This study aimed to determine and evaluate plasma levels of MMP-2 and TIMP-2 in patients with hypopharyngeal and laryngeal cancers compared with control groups. Subject and method: A prospective, cross-sectional, controlled study with longitudinal follow-up was conducted on 184 cancer patients (57 hypopharyngeal cancer, 127 laryngeal cancer), 58 disease controls (patients with other laryngeal conditions such as inflammation or fibrosis), and 50 healthy controls. Result: The median MMP-2 concentration was lower in the patient group (7.00ng/mL) and higher in the healthy control group (8.77ng/mL), with a statistically significant difference. Among males, MMP-2 levels varied significantly across groups, whereas no notable differences were observed among females; specifically, male healthy controls had higher levels than females (p=0.0079). TIMP-2 levels were lowest in the patient group (61.11ng/mL) and highest in the control group (75.48ng/mL), with overall levels being higher in females than in males, a statistically significant difference across the entire sample (p=0.0005). Conclusion: Plasma MMP-2 and TIMP-2 levels were decreased in patients with hypopharyngeal and laryngeal cancers compared with controls, suggesting their potential role as supportive biomarkers for diagnosis.
Article Details
References
2. Nguyễn Hoàng Sơn, Phạm Tuấn Cảnh (2019) Ung thư thanh quản: chẩn đoán và điều trị. Y học Thực hành, 1091(5): 21-25.
3. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3): 161-174.
4. Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta,1803(1): 55-71.
5. Roy R, Yang J, Moses MA (2009) Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27(31): 5287-5297.
6. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411: 375-379.
7. Yang Y, Zhou H, Xu H et al (2024) Association between elevated serum matrix metalloproteinase-2 and TNF-α, and clinical symptoms in male patients with treatment-resistant and chronic medicated schizophrenia. BMC Psychiatry 24: 147. doi:10.1186/s12888-024-05621-6.
8. Mahor D, Singh H, Singh D et al (2020) Elevated serum matrix metalloprotease (MMP-2) as a candidate biomarker for stable COPD. BMC Pulmonary Medicine; 20:223. doi:10.1186/s12890-020-01323-3.
9. Kessenbrock K, Plaks V, Werb Z (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141(1): 52-67.
10. Aksnes L et al (2024) Differences in metalloproteinases and their tissue inhibitors in delirium and acute hip fracture. Communications Medicine; 4:87. doi:10.1038/s43856-024-00587-6.
11. Negrin M et al (2024) Serum levels of matrix metalloproteinases and their inhibitors in human disease. Frontiers in Medicine 11: 1430603. doi: 10.3389/fmed.2024.1430603.
Article Sidebar
